Patents by Inventor Zamir Halpern

Zamir Halpern has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PERSON-SPECIFIC ASSESSMENT OF PROBIOTICS RESPONSIVENESS
    Publication number: 20210269860
    Abstract: A method of assessing whether a candidate subject is suitable for probiotic treatment is disclosed. The method comprises determining a signature of the gut microbiome of the candidate subject, wherein when the signature of the microbiome of the candidate subject is statistically significantly similar to a signature of a gut microbiome of a control subject known to be responsive to probiotic treatment, it is indicative that the subject is suitable for probiotic treatment.
    Type: Application
    Filed: July 8, 2019
    Publication date: September 2, 2021
    Applicants: Yeda Research and Development Co. Ltd., The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center
    Inventors: Eran SEGAL, Eran ELINAV, Zamir HALPERN
  • High affinity leptins and leptin antagonists
    Patent number: 8969292
    Abstract: Leptin muteins, in particular leptin antagonists, with increased binding affinity to leptin receptor are provided. These compounds as well as pharmaceutical composition comprising them are useful for the treatment of any disorder in which a non-desirable or deleterious activity of endogenous leptin or an altered innate immune response is implicated.
    Type: Grant
    Filed: April 17, 2011
    Date of Patent: March 3, 2015
    Assignees: The Medical Research, Infrastructure, and Health Services Fund of the Tel-Aviv Medical Center, Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
    Inventors: Arieh Gertler, Eran Elinav, Zamir Halpern
  • HIGH AFFINITY LEPTINS AND LEPTIN ANTAGONISTS
    Publication number: 20130133089
    Abstract: Leptin muteins, in particular leptin antagonists, with increased binding affinity to leptin receptor are provided. These compounds as well as pharmaceutical composition comprising them are useful for the treatment of any disorder in which a non-desirable or deleterious activity of endogenous leptin or an altered innate immune response is implicated.
    Type: Application
    Filed: April 17, 2011
    Publication date: May 23, 2013
    Applicants: THE MEDICAL RESEARCH, INFRASTRUCTURE, AND HEALTH SERVICES FUND OF THE TEL-AVIV, YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM
    Inventors: Arieh Gertler, Eran Elinav, Zamir Halpern